Table 3

Multiple regression with levels of anti-CCP2 in serum and synovial fluid together with number of ACPA reactivities in serum, synovial fluid, immune complex fraction in serum and in synovial fluid were used as independent variables and compared with clinical and laboratory measures (only significant p values (<0.05) are shown, and underlined if the regression coefficient and T statistics were negative)

AgeDisease durationDAS28Swollen joint countTender joint countGlobal VASESRCRPHAQLarsen-DaleTime to relapseSF PMNSF MNCSerum IL-6SF IL-6Serum TNFSF TNFSerum MMP3SF MMP3Serum PTX3SF PTX3Serum cathepsin LSF cathepsin LSerum cathepsin SSF cathepsin SSerum VEGFSF VEGF
Serum anti-CCP20.01820.0034
SF anti-CCP20.01570.04380.00260.0109
No of
ACPA in serum
No of
No of
ACPA in s-IC
No of ACPA in SF IC0.01660.04590.00070.0480.0441<0.00010.0377
  • ACPA, anti-citrullinated protein/peptide antibodies; CRP, C reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MNC, mononuclear cell; MMP3, matrix metalloproteinase 3; PMN, polymorphonuclear; PTX3, pentraxin 3; SF, synovial fluid; TNF, tumour necrosis factor; VAS, visual analogue scale; VEGF, vascular endothelial growth factor.